At a glance
ClinicalIndex Comparison RecordN/ACompleted· 344 enrolled
Drug / intervention
Octagam IVIG 5% or 10% +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Non-Interventional Study on the Tolerability and Efficacy of IVIG
In Brief
An observational study evaluating Octagam IVIG 5% or 10% and Panzyga for Primary and Secondary Immunodeficiency and Other Conditions Requiring Regular Administration of Octagam 5% or 10% IVIG. Completed, enrolled 344 participants across 38 sites in 5 countries.
Detailed Summary
Non-Interventional Study on the Tolerability and Efficacy of octagam® 10%
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesAustria, Canada, France, Spain, United Kingdom
Collaborators--
Timeline
N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartAug 2011
First PostedNov 2014
Primary CompletionJun 2020
TodayJul 2026
First PostedNov 27, 2014
Enrollment StartAug 1, 2011
Primary CompletionJun 5, 2020
TodayJul 2, 2026
Enrollment to primary: 8.8 yearsPosted 11.6 years ago
Interventions
Octagam IVIG 5% or 10%biological
Octagam IVIG 5% or 10%
Panzygabiological
Panzyga